ALNYbenzinga

Alnylam Secures FDA Approval Of sNDA For Its RNAi Therapeutic, AMVUTTRA, For Treatment Of ATTR-CM In Adults To Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations And Urgent Heart Failure Visits

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on March 20, 2025 by benzinga